Navigation Links
Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P.
Date:1/3/2012

ELKRIDGE, Md., Jan. 3, 2012 /PRNewswire/ -- GP Strategies Corporation (NYSE: GPX), a global performance improvement solutions provider of sales and technical training, e-Learning solutions, management consulting and engineering services, today announced that Sagard Capital Partners, L.P. ("Sagard Capital") has agreed to purchase 350,000 shares in a private transaction from Bedford Oak Partners, L.P. The closing of the transaction is subject to customary conditions and is expected to occur within the next week (but in any event prior to January 13th). This purchase increases Sagard Capital's ownership to 3,333,621 shares or 17.8% of GP Strategies' outstanding common stock.  GP Strategies is not a participant in the transaction.

(Logo:  http://photos.prnewswire.com/prnh/20110404/MM77341LOGO-b )

"We are extremely pleased that an investor like Sagard Capital continues to share our vision on the two-year anniversary of their original private placement.  We view their increased investment as a tangible sign of continued confidence in the direction of GP Strategies," commented Scott N. Greenberg, Chief Executive Officer of GP Strategies.

"We remain enthusiastic about our investment in GP Strategies.  GP Strategies has truly become a leading provider of custom training, consulting and technical services by building a foundation of strong global relationships with their clients," said Dan Friedberg, Managing Partner of Sagard Capital Partners, L.P.  Dan Friedberg is on the Board of Directors and Executive Committee of GP Strategies.

Bedford Oak Partners, L.P., for reasons of its own internal liquidity, decided to sell its shares in GP Strategies before the 2011 calendar year end. Harvey P. Eisen, Chairman of the Board of GP Strategies since April 2005, is also the Chairman and Managing Member of Bedford Oak Advisors, LLC, the investment manager of Bedford Oak Partners, L.P. 

About Sagard Capital Partners, L.P.

Sagard Capital is a long-term impact investor in public and private small and mid-sized companies.  Sagard is an evergreen fund with an indefinite holding period for its investments.  Sagard specializes in flexible transaction structures, making minority investments with equity or debt to best address a company's needs.  Sagard partners with management teams committed to driving long-term shareholder value, through a combination of capital, a global network of relationships, and a team built to deliver value-add support.  Additional information may be found at www.sagardcapital.com.

About GP Strategies

GP Strategies, a NYSE-listed company (GPX), is a global performance improvement solutions provider of sales and technical training, e-Learning solutions, management consulting and engineering services.  GP Strategies' solutions improve the effectiveness of organizations by delivering innovative and superior training, consulting and business improvement services, customized to meet the specific needs of its clients.  Clients include Fortune 500 companies, manufacturing, process and energy industries, and other commercial and government customers.  Additional information may be found at www.gpstrategies.com.

Forward Looking Statements

We make statements in this press release that are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements reflect our current expectations concerning future events and results. We use words such as "expect," "intend," "believe," "may," "should," "could," "anticipates," and similar expressions to identify forward-looking statements, but their absence does not mean a statement is not forward-looking. These statements are not guarantees of our future performance and are subject to risks, uncertainties, and other important factors that could cause our actual performance or achievements to be materially different from those we project. For a full discussion of these risks, uncertainties, and factors, we encourage you to read our documents on file with the Securities and Exchange Commission, including those set forth in our periodic reports under the forward-looking statements and risk factors sections. Except as required by law, we do not intend to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE GP Strategies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
6. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
7. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
8. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
9. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
10. New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers
11. Accumetrics Announces $16.5M in New Capital Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):